Cargando…

In Situ-Based Gels for Nose to Brain Delivery for the Treatment of Neurological Diseases

In situ-based gel drug delivery systems that can bypass the blood-brain barrier, deliver the therapeutics to the desired site, reduce peripheral toxicity and control drug release kinetics have been developed. Some of the therapeutics used to treat neurological diseases suffer from poor bioavailabili...

Descripción completa

Detalles Bibliográficos
Autor principal: Aderibigbe, Blessing Atim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6027251/
https://www.ncbi.nlm.nih.gov/pubmed/29601486
http://dx.doi.org/10.3390/pharmaceutics10020040
_version_ 1783336568325406720
author Aderibigbe, Blessing Atim
author_facet Aderibigbe, Blessing Atim
author_sort Aderibigbe, Blessing Atim
collection PubMed
description In situ-based gel drug delivery systems that can bypass the blood-brain barrier, deliver the therapeutics to the desired site, reduce peripheral toxicity and control drug release kinetics have been developed. Some of the therapeutics used to treat neurological diseases suffer from poor bioavailability. Preclinical reports from several researchers have proven that the delivery of drugs to the brain via the nose-to-brain route using in situ gels holds great promise. However, safety issues on the toxicity of the nasal mucosa, transportation of the drugs to specific brain regions and determination of the required dose are factors that must be considered when designing these gels. This review will be focused on in situ-based gels that are used for the delivery of therapeutics via the nose-to-brain route, preclinical reports and challenges.
format Online
Article
Text
id pubmed-6027251
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-60272512018-07-13 In Situ-Based Gels for Nose to Brain Delivery for the Treatment of Neurological Diseases Aderibigbe, Blessing Atim Pharmaceutics Review In situ-based gel drug delivery systems that can bypass the blood-brain barrier, deliver the therapeutics to the desired site, reduce peripheral toxicity and control drug release kinetics have been developed. Some of the therapeutics used to treat neurological diseases suffer from poor bioavailability. Preclinical reports from several researchers have proven that the delivery of drugs to the brain via the nose-to-brain route using in situ gels holds great promise. However, safety issues on the toxicity of the nasal mucosa, transportation of the drugs to specific brain regions and determination of the required dose are factors that must be considered when designing these gels. This review will be focused on in situ-based gels that are used for the delivery of therapeutics via the nose-to-brain route, preclinical reports and challenges. MDPI 2018-03-30 /pmc/articles/PMC6027251/ /pubmed/29601486 http://dx.doi.org/10.3390/pharmaceutics10020040 Text en © 2018 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Aderibigbe, Blessing Atim
In Situ-Based Gels for Nose to Brain Delivery for the Treatment of Neurological Diseases
title In Situ-Based Gels for Nose to Brain Delivery for the Treatment of Neurological Diseases
title_full In Situ-Based Gels for Nose to Brain Delivery for the Treatment of Neurological Diseases
title_fullStr In Situ-Based Gels for Nose to Brain Delivery for the Treatment of Neurological Diseases
title_full_unstemmed In Situ-Based Gels for Nose to Brain Delivery for the Treatment of Neurological Diseases
title_short In Situ-Based Gels for Nose to Brain Delivery for the Treatment of Neurological Diseases
title_sort in situ-based gels for nose to brain delivery for the treatment of neurological diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6027251/
https://www.ncbi.nlm.nih.gov/pubmed/29601486
http://dx.doi.org/10.3390/pharmaceutics10020040
work_keys_str_mv AT aderibigbeblessingatim insitubasedgelsfornosetobraindeliveryforthetreatmentofneurologicaldiseases